Birdshot Chorioretinitis in Patients Aged 80 and Older

ABSTRACT

Purpose

To assess the manifestations of birdshot chorioretinitis (BSCR) in patients aged 80 and over.

Design

Among patients with BSCR followed in the CO-BIRD prospective cohort (ClinicalTrials.gov Identifier: NCT05153057), we analyzed the subgroup of patients aged 80 and over.

Methods

Patients were assessed in a standardized manner. Confluent atrophy was defined as hypoautofluorescent spots on fundus autofluorescence (FAF).

Results

We included 39 (8.8%) of the 442 enrolled CO-BIRD patients. The mean age was 83.8 ± 3.7 years. The mean logMAR BCVA was 0.52 ± 0.76, with 30 patients (76.9%) having 20/40 or better in at least one eye. Thirty-five (89.7%) patients were receiving no treatment. Confluent atrophy in the posterior pole, disrupted retrofoveal ellipsoid zone and choroidal neovascularization were associated with logMAR BCVA >0.3 (p < .0001).

Conclusion

In patients aged 80 and over we observed a striking heterogeneity of outcomes, but most retained a BCVA that allowed them to drive.

KEYWORDS:

• Birdshot chorioretinitis
• choroid
• immunosuppressive therapy
• long-term
• posterior uveitis

Disclosure statement

No potential conflict of interest was reported by the author(s).

Additional information

Funding

Association d'ophtalmologie de Cochin, Birdshot Research Fund at Wilmer Eye Institute.